Longeveron (LGVN) investor relations material

Company overview and business model

• Clinical-stage biotechnology company focused on developing regenerative medicines, with lead candidate laromestrocel (Lomecel-B®) targeting multiple indications including HLHS, Alzheimer's disease, pediatric DCM, and aging-related frailty.

• Operates a cGMP manufacturing facility in Miami for early-phase clinical supply and leverages third-party CDMOs for commercial-scale production.

• Pursues strategic collaborations and partnerships for clinical advancement and commercialization of laromestrocel.

• Holds a broad intellectual property portfolio with patents filed in multiple jurisdictions for key indications.

Financial performance and metrics

• Working capital deficiency, stockholders' deficit, and recurring losses from operations raise substantial doubt about ability to continue as a going concern.

• Recent private placement raised approximately $15.9 million, with potential for an additional $15 million upon meeting certain milestones.

• Cash and equivalents expected to fund operations into Q4 2026, but additional funding will be required for ongoing operations and clinical programs.

Use of proceeds and capital allocation

• No proceeds from resale of shares by selling stockholders; up to $1.3 million may be received if all PA Warrants are exercised for cash.

• Any proceeds from warrant exercises intended for clinical and regulatory development of laromestrocel, working capital, and general corporate purposes.